# Junta clínica — PT-pseudo_83f690a06c81 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_83f690a06c81",
  "pid": "PT-pseudo_83f690a06c81",
  "task": 1,
  "psa": 12.0,
  "age": 66,
  "months": 1,
  "pirads": "5",
  "psad": 0.173,
  "psav": 2.64,
  "psap": 9.0,
  "vol": 69.24,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8477834,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 12 ng/mL. PI-RADS 5. PSAD 0.17. Prostate volume 69 mL. csPCa 0.85.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "70 kg",
    "height": "172 cm",
    "bmi": "23.7",
    "bp": "116/73 mmHg",
    "hr": "69 bpm",
    "smoking": "Non-smoker",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "15 Feb 2025",
  "enc_ref": "Dr. N. Kuiper (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Documented PSA escalation alongside a previously positive prostate biopsy warrants clinical reassessment."
    },
    {
      "s": "History",
      "t": "A 66-year-old graphic designer first entered diagnostic evaluation in early 2024 due to an elevated PSA, a value that has now advanced to 12.0 ng/mL. Lower urinary tract complaints are moderate, yielding an IPSS score of 16, with nocturia and a diminished stream being the primary concerns; he explicitly denies haematuria or pelvic discomfort. Leisure activities include tennis twice weekly, and his alcohol intake remains at approximately five units of alcohol per week. Systemic health remains stable, corroborated by an autumn 2024 cardiology review showing no significant deviations, routine dental maintenance, and a recent chest X-ray. He shares his home with his wife, while adult children stop by each week. Reaching the clinic requires a train journey lasting over an hour."
    },
    {
      "s": "Physical examination",
      "t": "Per rectum: the gland presents as symmetrically enlarged, exhibiting a smooth, firm consistency without nodularity or asymmetry. Vital parameters remain stable, recording a blood pressure of 116/73 mmHg and a regular heart rate of 69 bpm. Systemic examination reveals no pallor, lymphadenopathy, or abdominal masses."
    }
  ],
  "occupation": "graphic designer",
  "marital": "Married",
  "living": "Lives with partner; adult children visit weekly",
  "next_of_kin": "Long-time friend (no close family)",
  "recent_other": [
    "Cardiology — annual review (stable, autumn 2024)",
    "Dental — biannual check-up",
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "5 units / week",
  "exercise": "Tennis 2x/week",
  "ipss": "IPSS score: 16/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Radboudumc",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_83f690a06c81
Task: 1

Encounter: Urology - outpatient on 15 Feb 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 12.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.173 ng/mL²
  - PSA velocity: 2.64 ng/mL/yr
  - Prior PSA: 9.0 ng/mL
  - Prostate volume: 69.24 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8477834 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 12 ng/mL. PI-RADS 5. PSAD 0.17. Prostate volume 69 mL. csPCa 0.85.

Vitals: weight 70 kg, height 172 cm, BMI 23.7, BP 116/73 mmHg, HR 69 bpm. Smoking: Non-smoker.

Chief complaint: Documented PSA escalation alongside a previously positive prostate biopsy warrants clinical reassessment.

History: A 66-year-old graphic designer first entered diagnostic evaluation in early 2024 due to an elevated PSA, a value that has now advanced to 12.0 ng/mL. Lower urinary tract complaints are moderate, yielding an IPSS score of 16, with nocturia and a diminished stream being the primary concerns; he explicitly denies haematuria or pelvic discomfort. Leisure activities include tennis twice weekly, and his alcohol intake remains at approximately five units of alcohol per week. Systemic health remains stable, corroborated by an autumn 2024 cardiology review showing no significant deviations, routine dental maintenance, and a recent chest X-ray. He shares his home with his wife, while adult children stop by each week. Reaching the clinic requires a train journey lasting over an hour.

Physical examination: Per rectum: the gland presents as symmetrically enlarged, exhibiting a smooth, firm consistency without nodularity or asymmetry. Vital parameters remain stable, recording a blood pressure of 116/73 mmHg and a regular heart rate of 69 bpm. Systemic examination reveals no pallor, lymphadenopathy, or abdominal masses.

Patient info: graphic designer; Married; Lives with partner; adult children visit weekly.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 5 units / week; exercise Tennis 2x/week; IPSS score: 16/35 (moderate LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024); Dental — biannual check-up; Radiology — chest X-ray (routine).
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.60
  uncertainty  +/- 0.10 epistemic (95% band 0.41-0.80); among patients I cannot tell apart the outcome was 0.97 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.89: PI-RADS 5, PSA 11.0, PSAD 0.108, age 70, DRE Normal -> BIOPSY (borderline). He wrote: "Patient on Activ Surveillance with severe LUTS symptoms. There are two options , recommend surgery direkt or do a new biopsy."
  2. distance 1.02: PI-RADS 5, PSA 12.0, PSAD 0.28, age 61, DRE Normal -> DEFER (borderline). He wrote: "Young patient with elevated PSA (>10), elevated PSA density, PIRADS5 and ISUP GG2 disease -> low threshold for recommending curative treatment. IF patient does not want…"
  3. distance 1.02: PI-RADS 5, PSA 19.0, PSAD 0.37, age 65, DRE Normal -> DEFER (clear). He wrote: "Patient needs treatment without repeat biopsy as earlier biopsy showed ISUP4"

PRECEDENT: DEFER (weighted vote 0.36 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guideline discusses the use of MRI and biopsy in relation to risk stratification based on PI-RADS score and PSA density. "Linking PI-RADS score (1-2, 3, and 4-5) to PSA-D categories (< 0.10, 0.10-0.15, 0.15-0.20 and > 0.20ng/mL) (Table 5.5) [230]. This risk-adapted matrix table may guide the decision to perform a biopsy." This requires assessing the patient's PI-RADS score and PSA density against these thresholds to guide the decision.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED's suggestion of biopsy is not settled because the guideline emphasizes that the decision is guided by a risk-adapted matrix involving PI-RADS and PSA density, which the panel variables alone do not fully resolve. EXPERT-COHORT's finding that the prior positive biopsy means the panel does not determine the decision is consistent with the guideline's focus on documented prior diagnosis.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - whether the PSA trend is significant: a rising PSA velocity is a factor in risk stratification
laboratory_results - whether the PSA density falls into a specific category: this determines the risk-adapted matrix application

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the grade of the prior biopsy and the significance of the PSA trend to determine the next step.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size or extraprostatic extension require re-sampling?
  psa_trend (get_psa_trend) -> Is the PSA velocity significant enough to warrant further action?
  previous_notes (get_previous_notes) -> What is the grade of the prior biopsy, and is there an active surveillance protocol?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the grade (Gleason/ISUP) of the prior prostate biopsy?
  Q2. Is the PSA trend significant, and does the PSA density fall into a specific risk category according to the EAU matrix?

On the plan itself: The moderator asked for laboratory_results, which the reading urologist does not open in this situation; dropped — every reveal beyond his is scored against us.

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI Prostate | Institution: Radboudumc | Date: 10 Feb 2025
COMPARISON: new
LESION: PI-RADS 5 focus situated in the right mid-apical peripheral zone.

psa_trend
PSA 7.0 (Jan 2024) rising to 12.0 (Feb 2025), steepest in the last year.

previous_notes
PRIOR GRADE: not recorded
BIOPSY SESSIONS: not recorded
SURVEILLANCE: not recorded
TREATMENT: none recorded

WHAT I DID NOT OPEN
laboratory_results, because the reading urologist does not open it in this situation.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 focus situated in the right mid-apical peripheral zone, as per radiology_report.
PSA velocity is significant, as the PSA trend shows a rise from 7.0 ng/mL in Jan 2024 to 12.0 ng/mL in Feb 2025, as per psa_trend.
AGAINST sampling this patient now
Prior biopsy grade is not recorded, as per previous_notes.

WHERE THIS LEANS
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 12.00 ng/mL over 4 points spanning 13 months; velocity +4.36 ng/mL per year; doubling time about 16 months.
PROJECTION at 6 months: 23.3 ng/mL, conformal 95% band 6.7-81.2.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.60
  uncertainty  +/- 0.09 epistemic (95% band 0.42-0.78), of which 0.01 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 56% of the time over the 25 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.60  ('supports' tier; weight 2.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.60  ('supports' tier, fusion_nolab; weight 3.0)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.36  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.60 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_nolab). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved—radiology_report, psa_trend, and previous_notes—directly address the moderator's questions. The registrar reported that the prior biopsy grade is "not recorded" and that biopsy sessions and surveillance are "not recorded." The PSA trend shows a significant rise from 7.0 ng/mL to 12.0 ng/mL.

ALIGNMENT WITH THE PANEL
The panel protocol concluded BIOPSY based on a weighted vote of EXPERT-STRUCTURED and EXPERT-FUSION, which relied on the fact that the documented prior grade was not recorded. The retrieved finding that aligns with this is the registrar's report stating, "Prior grade is not recorded."

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the grade (Gleason/ISUP) of the prior prostate biopsy? Answered by the registrar: "not recorded."
Q2. Is the PSA trend significant, and does the PSA density fall into a specific risk category according to the EAU matrix? The PSA trend is significant (rise from 7.0 to 12.0 ng/mL). The PSA density (0.173) is within the 0.15-0.20 ng/mL² category according to the EAU guideline context.

WHAT CARRIES WEIGHT, AND WHY
The grade of the prior biopsy is critical because the EAU guideline states that a grade of ISUP 2 or above sends the patient to treatment, not further tissue sampling. The significant PSA velocity is also important as it reflects the disease behavior.

MY SUGGESTION TO THE CHAIR
Given that the prior biopsy grade is not recorded, and the PSA trend is significant, the panel's decision to proceed with a biopsy is supported by the expert consensus, as the lack of a recorded grade necessitates further investigation according to the protocol.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

66y male, PSA 12.0, PI-RADS 5, prior biopsy grade not recorded. New PI-RADS 5 lesion with rising PSA warrants biopsy to establish baseline ISUP grade. No prior biopsy grade recorded, making sampling necessary for management planning.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
